Cardiac amyloidosis is a serious and progressive infiltrative disease caused by the deposition of amyloid fibrils in the heart. In the last years, a significant increase in the diagnosis rate has been observed owing to a greater awareness of its broad clinical presentation. Cardiac amyloidosis is frequently associated to specific clinical and instrumental features, so called “red flags”, and it appears to occur more commonly in particular clinical settings such as multidistrict orthopedic conditions, aortic valve stenosis, heart failure with preserved or mildly reduced ejection fraction, arrhythmias, plasma cell disorders. Multimodality approach and new developed techniques such PET fluorine tracers or artificial intelligence may contribute to strike up extensive screening programs for an early recognition of the disease.
Caponetti A.G., Accietto A., Saturi G., Ponziani A., Sguazzotti M., Massa P., et al. (2023). Screening approaches to cardiac amyloidosis in different clinical settings: Current practice and future perspectives. FRONTIERS IN CARDIOVASCULAR MEDICINE, 10, 1-10 [10.3389/fcvm.2023.1146725].
Screening approaches to cardiac amyloidosis in different clinical settings: Current practice and future perspectives
Caponetti A. G.;Accietto A.;Saturi G.;Ponziani A.;Sguazzotti M.;Giovannetti A.;Ditaranto R.;Parisi V.;Guaraldi P.;Cortelli P.;Gagliardi C.;Longhi S.;Galie N.;Biagini E.
2023
Abstract
Cardiac amyloidosis is a serious and progressive infiltrative disease caused by the deposition of amyloid fibrils in the heart. In the last years, a significant increase in the diagnosis rate has been observed owing to a greater awareness of its broad clinical presentation. Cardiac amyloidosis is frequently associated to specific clinical and instrumental features, so called “red flags”, and it appears to occur more commonly in particular clinical settings such as multidistrict orthopedic conditions, aortic valve stenosis, heart failure with preserved or mildly reduced ejection fraction, arrhythmias, plasma cell disorders. Multimodality approach and new developed techniques such PET fluorine tracers or artificial intelligence may contribute to strike up extensive screening programs for an early recognition of the disease.File | Dimensione | Formato | |
---|---|---|---|
fcvm-10-1146725.pdf
accesso aperto
Tipo:
Versione (PDF) editoriale
Licenza:
Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione
89.31 MB
Formato
Adobe PDF
|
89.31 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.